Sanofi Ventures
CVC
Active
Paris, France
85
45M
58
2.83
10
0.32
16
- Stages of investment
- Areas of investment
Summary
In 1994 was created Sanofi-Genzyme BioVentures, which is appeared as VC. The fund was located in North America if to be more exact in United States. Sanofi-Genzyme BioVentures appeared to be a CVC structure as part of the corporation. The leading representative office of defined VC is situated in the Cambridge.
The average startup value when the investment from Sanofi-Genzyme BioVentures is 100-500 millions dollars. The increased amount of exits for fund were in 2017. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund. Opposing the other organizations, this Sanofi-Genzyme BioVentures works on 3 percentage points more the average amount of lead investments.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Sanofi-Genzyme BioVentures, startups are often financed by New Enterprise Associates, GE Ventures, U.S. Venture Partners (USVP). The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Novartis Venture Fund, Atlas Venture. In the next rounds fund is usually obtained by Wellington Management, Rock Springs Capital, RA Capital Management.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Omada Health, Expansion Therapeutics, Evidation Health.
The overall number of key employees were 4.
Investor highlights
- Industry focus
- Stage focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 85
- Lead investments
- 10
- Exits
- 16
- Rounds per year
- 2.83
- Follow on index
- 0.32
- Investments by industry
- Biotechnology (70)
- Health Care (58)
- Therapeutics (34)
- Medical (32)
- Pharmaceutical (29) Show 29 more
- Investments by region
-
- United States (73)
- United Kingdom (3)
- Denmark (4)
- Netherlands (1)
- France (2) Show 1 more
- Peak activity year
- 2023
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 56M
- Group Appearance index
- 0.98
- Avg. company exit year
- 6
- Avg. multiplicator
- 1.71
- Strategy success index
- 0.80
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| QurAlis | 09 Mar 2023 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | 88M | United States, Massachusetts, Cambridge |
| Sudo Biosciences | 13 Feb 2024 | Biopharma | Early Stage Venture | 30M | United States, Menlo Park, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.